Towa Pharmaceutical Revamps Board With New Director and Governance-Focused Appointments

Towa Pharmaceutical Co ( (JP:4553) ) has issued an announcement.

Towa Pharmaceutical has announced changes to its board, proposing the reappointment of President and Representative Director Itsuro Yoshida and other incumbent directors, while promoting Hideshi Nakamura, currently General Manager of the President’s Office and Operating Officer in charge of the Corporate Strategy Division, to director. The slate also maintains outside director Norikazu Eiki as an independent officer, reinforcing continuity in management and governance.

For its Audit and Supervisory Committee, the company will seek to reappoint current members Masao Tanaka, Kaori Oishi, and Nobuki Ando, while newly nominating veteran banker Muneya Taniguchi as an outside director and planned independent officer. Taniguchi’s extensive background at MUFG Bank and related financial institutions is expected to bolster board oversight and financial governance as the company prepares these changes for shareholder approval at the June 24, 2026, general meeting.

The most recent analyst rating on (JP:4553) stock is a Buy with a Yen3500.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.

More about Towa Pharmaceutical Co

Towa Pharmaceutical Co., Ltd. is a Japan-based drug maker focused on manufacturing and marketing pharmaceuticals. The company operates under Japan’s corporate governance and listing rules, including the designation of independent officers as defined by the Tokyo Stock Exchange, reflecting its engagement with public capital markets and listed-company oversight standards.

Average Trading Volume: 131,973

Technical Sentiment Signal: Buy

Current Market Cap: Yen190.2B

Learn more about 4553 stock on TipRanks’ Stock Analysis page.